Skip to main content
. 2018 Dec 7;75(11):481–494. doi: 10.1002/cm.21504

Figure 4.

Figure 4

Model of PLK1 chemical genetics. The catalytic domain of PLK1 can be inhibited by treatment with an ATP analogue, such as the drug BI2536. By mutating and enlarging this catalytic domain, PLK1 can be inhibited in cells expressing this mutant using a purine analogue. Adapted from Burkard et al. (2007)